Drugs News and Research RSS Feed - Drugs News and Research

Sanofi, Regeneron reports positive Phase 2 study of dupilumab in patients with CSwNP

Sanofi, Regeneron reports positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids. [More]
U-M researchers describe new approach to discovering potential cancer treatments

U-M researchers describe new approach to discovering potential cancer treatments

Researchers at the University of Michigan have described a new approach to discovering potential cancer treatments that requires a fraction of the time needed for more traditional methods. [More]
CNIO researchers discover new specific marker for cancer stem cells

CNIO researchers discover new specific marker for cancer stem cells

Tumours are mosaics of cells that are morphologically and molecularly very different. In this cellular heterogeneity, it is calculated that only 1-2% of the tumour mass is made up of cancer stem cells, which over the past years have been suggested to be responsible for the origin of cancer and for the resistance to conventional chemical therapies. [More]
Par Pharmaceutical starts shipping generic version of Exforge

Par Pharmaceutical starts shipping generic version of Exforge

Par Pharmaceutical Companies, Inc. today announced that it has begun shipping all four strengths of amlodipine and valsartan tablets, the generic version of Novartis' Exforge. Par received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for amlodipine and valsartan and was granted 180 days of marketing exclusivity. [More]
Researchers uncover molecular interaction between key proteins in cell division

Researchers uncover molecular interaction between key proteins in cell division

Researchers from Guillermo Montoya's team at the Spanish National Cancer Research Centre (CNIO), in collaboration with Isabelle Vernos' Group from the Centre for Genomic Regulation (CRG), have uncovered the molecular interaction between TACC3 and chTOG, key proteins in forming the internal cellular framework that enables and sustains cell division. [More]
Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

Trastuzumab offers better outcome than lapatinib for HER2-positive breast cancer patients

Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher. [More]
UCSF gets CDC grant to provide expert guidance to clinicians who prescribe anti-HIV medications

UCSF gets CDC grant to provide expert guidance to clinicians who prescribe anti-HIV medications

The UCSF Clinician Consultation Center at San Francisco General Hospital and Trauma Center has been funded by the Centers for Disease Control and Prevention to provide a PrEPline, a telephone consultation service that gives expert guidance to healthcare providers across the nation who prescribe antiretroviral medications to HIV uninfected individuals to prevent HIV. [More]
AAN releases new position statement on opioids for chronic non-cancer pain

AAN releases new position statement on opioids for chronic non-cancer pain

According to a new position statement from the American Academy of Neurology, the risk of death, overdose, addiction or serious side effects with prescription opioids outweigh the benefits in chronic, non-cancer conditions such as headache, fibromyalgia and chronic low back pain. [More]
Cedars-Sinai experts to present free conference on dystonia for patients, families and caregivers

Cedars-Sinai experts to present free conference on dystonia for patients, families and caregivers

A multidisciplinary team of experts affiliated with the Cedars-Sinai Movement Disorders Program will present a free conference for patients, families and caregivers on treatment options for dystonia, which causes painful and potentially crippling muscle contractions. [More]
VCU receives $6 million grant to develop safe, effective treatments for cocaine addiction

VCU receives $6 million grant to develop safe, effective treatments for cocaine addiction

Virginia Commonwealth University has received a five-year, $6 million grant for clinical research and education directed toward the identification, evaluation and development of safe and effective treatments for cocaine addiction. [More]
Three institutions collaborate to study genetics of bipolar disorder, schizophrenia

Three institutions collaborate to study genetics of bipolar disorder, schizophrenia

Researchers at the University of Michigan School of Public Health and Medical School and collaborators at two other institutions will undertake the largest whole genome sequencing study funded to date, as they seek to better understand bipolar disorder and schizophrenia. [More]
Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [More]
Researchers explain how molecular structure of the heart muscle changes in heart failure

Researchers explain how molecular structure of the heart muscle changes in heart failure

In a new study published in Proceedings of the National Academy of Sciences USA, researchers at the University of Alberta's Faculty of Medicine & Dentistry have explained how the function of a key protein in the heart changes in heart failure. [More]
State highlights: Calif. health insurers and contraception coverage; Alaska sues Xerox over Medicaid payment systems

State highlights: Calif. health insurers and contraception coverage; Alaska sues Xerox over Medicaid payment systems

Health insurance policies in California will have to cover all federally approved contraceptives for women by 2016 without charging co-payments under legislation signed this week by Gov. Jerry Brown, countering trends in other states and the U.S. Supreme Court. The bill, SB1053 by Sen. Holly Mitchell, D-Los Angeles, expands state laws that required coverage for most birth-control drugs and devices approved by the U.S. Food and Drug Administration. The new law mandates coverage for all FDA-approved contraception, prohibits co-payments and includes managed-care Medi-Cal plans, which are not expressly covered by current laws (Egelko, 9/27). [More]
Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. [More]
Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain. [More]
New approach to solve global challenges in food security, emerging diseases and biodiversity loss

New approach to solve global challenges in food security, emerging diseases and biodiversity loss

Solving global challenges in food security, emerging diseases and biodiversity loss requires evolutionary thinking, argues a new study published online in Science Express that was co-authored by Bruce Tabashnik of the University of Arizona College of Agriculture and Life Sciences. [More]

Apexus secures HRSA contract, continues to serve as prime vendor of 340B Drug Pricing Program

Apexus, LLC, the prime vendor for the 340B Drug Pricing Program, has announced that it has been selected by the Health Resources and Services Administration (HRSA) to continue serving in its role as the prime vendor through September 29, 2019. [More]
Antibiotic exposure in infancy linked to childhood obesity

Antibiotic exposure in infancy linked to childhood obesity

Repeated exposure to broad-spectrum antibiotics in the first two years of life is associated with early childhood obesity, say researchers from The Children's Hospital of Philadelphia in a retrospective study based on data from electronic health records from the extensive CHOP Care Network. [More]
Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

A world-first study in today's New England Journal of Medicine heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma. [More]